Regenxbio Inc
RGNX
Get informed when a big investor buys or sells
+ FollowMarket Cap$440.98M
Close$
$25.02
193.3% upside
Current Fair Value
193.3% upsideUndervalued by 193.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $440.98 Million |
|---|---|
| Enterprise Value | $552.28 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.76 |
| Beta | 0.93 |
| Outstanding Shares | 52,820,000 |
Return
| Return on Equity | -273.72% |
|---|---|
| Return on Assets | -50.81% |
| Return on Invested Capital | -53.59% |
Valuation & Multiples
| P/E Ratio | -2.25 |
|---|---|
| PEG | 1.7 |
| Price to Sales | 2.84 |
| Price to Book Ratio | 8.53 |
| Enterprise Value to Revenue | 3.17 |
| Enterprise Value to EBIT | -3.39 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$97.63 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.21
Average shareholder expectationRevenue Estimate
$15.86 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3293▼ 34.85% |
|---|---|
| Total Calls | 523,000▲ 26.05% |
| Total Puts | 172,200▼ 38.76% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.62%▼ 0.62% |
|---|---|
| Total Invested | $509.36M▲ 43.43% |
| Investors Holding | 176▼ 13.00% |
ESG Score
No data
About Regenxbio Inc
CEO: Kenneth Mills